Serenity is improving the production and performance of protein-based therapeutics.

Protein-based therapeutics are currently used to treat our society's major diseases, including cancers, chronic inflammatory conditions, diabetes, and infectious diseases. These therapeutics comprise a large and rapidly growing arm of the pharmaceutical industry, projected to reach a market value of $208 billion USD by the year 2020. However, despite the blockbuster status of biologics, there are still problems that need to be addressed.

The largest problem associated with most biologics is structural instability. A large amount of product is lost throughout the manufacturing chain in addition to the generation of potentially immunogenic aggregates in the final formulation. Existing strategies attempt to solve the stability problem by either re-engineering the main ingredient or by adding salts, sugars, surfactants, and/or albumin to the formulation. These solutions each have limitations in their potential to increase stability, whether it be the thermodynamic limitations in structural optimization or the limited list of excipients that can be added to final formulations. 

Serenity Bioworks has large plans for the pharmaceutical industry. Our overall aim is to actualize innovative ideas that will improve the healthcare system for all parties involved. Serenity's first offering is a novel stabilization platform for biologics, called CargoTek. CargoTek will enhance the long-term efficacy and safety for biologics, resulting in safe and longer-lasting treatments for patients.